Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

Daily Archives October 12, 2020

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited ...

La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) — Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage biopharmaceutical company, and Curon Biopharmaceutical Limited (Curon), a clinical-stage innovative biopharmaceutical company with facility in Shanghai announced today that they have entered into an exclusive licensing agreement for the development […]Read More

Icebreaker Returns From A-Year-Long Expedition to North Pole

An icebreaker belonging to Germany’s Alfred Wegener Institute (AWI) returned to Germany Monday with what the scientists on board say is proof of a dying Arctic Ocean and warnings of ice-free summers, after a more than yearlong expedition that included ...Read More

Microsoft Attempts Takedown of Global Criminal Botnet

Microsoft announced legal action Monday seeking to disrupt a major cybercrime digital network that uses more than 1 million zombie computers to loot bank accounts and spread ransomware, which experts consider a major threat to the U.S. presidential ele...Read More

WHO Chief: Pursuing Herd Immunity Through Coronavirus Exposure ...

The head of the World Health Organization is warning against a strategy of pursuing herd immunity to stop the coronavirus pandemic, calling the idea unethical.At a news briefing Monday in Geneva, WHO Director-General Tedros Adhanom Ghebreyesus said hea...Read More